| Drug Type Proteolysis-targeting chimeras (PROTAC) | 
| Synonyms VHL-targeting PROTAC analogue 7, MZ2 | 
| Target | 
| Action degraders | 
| Mechanism BRD4 degraders(Bromodomain-containing protein 4 degraders), VHL degraders(von Hippel-Lindau tumor suppressor degraders), Epigenetic drug | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization- | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 
| Molecular FormulaC51H64ClN9O9S2 | 
| InChIKeyLSELSHXLKGXPPF-BOBBFQORSA-N | 
| CAS Registry1797406-70-2 | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Hematologic Neoplasms | Preclinical | United States  | 08 Jun 2017 | |
| Hematologic Neoplasms | Preclinical | United Kingdom  | 08 Jun 2017 | |
| Solid tumor | Preclinical | United States  | 08 Jun 2017 | |
| Solid tumor | Preclinical | United Kingdom  | 08 Jun 2017 | |
| Neoplasms | Preclinical | United States  | 16 Jun 2015 | 





